GLP-1
Tirzepatide (Mounjaro/Zepbound) is the most effective weight loss medication ever approved. This complete guide covers mechanism of action, SURMOUNT trial results, dosing, side effects, and how it compares to semaglutide.
GLP-1
Semaglutide and tirzepatide have transformed obesity medicine. The average person on tirzepatide loses 20–22% of their body weight; on semaglutide, 15–17%. Those are numbers that previously required bariatric surgery. But there's a complication the prescribing literature doesn't emphasize enough: a meaningful portion of that
GLP-1
Tirzepatide is a dual GIP/GLP-1 receptor agonist that outperforms semaglutide in head-to-head trials. This complete guide covers mechanism, dosing, side effects, and the SURMOUNT-5 results.
GLP-1
Tirzepatide has quickly become one of the most discussed medications in metabolic medicine. Sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for obesity), it represents a new class of treatment: the dual GIP/GLP-1 receptor agonist. Unlike earlier GLP-1 drugs like semaglutide, tirzepatide activates two distinct
GLP-1
Two medications have transformed obesity treatment over the past few years: semaglutide (sold as Ozempic for diabetes, Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss). Both deliver remarkable results, but they work differently — and the evidence now clearly shows one outperforms the other on the
GLP-1
GLP-1
GLP-1
GLP-1
Tirzepatide produces 22.5% mean weight loss at 15 mg — but only with correct titration and injection technique. This complete 2026 guide covers everything from the 2.5 mg initiation dose through the full schedule, autoinjector protocol, and side effect management.
GLP-1
Two injectable medications now dominate the weight-loss conversation: semaglutide (sold as Ozempic for diabetes and Wegovy for obesity) and tirzepatide (Mounjaro for diabetes, Zepbound for obesity). Both belong to the GLP-1 class, both require once-weekly injections, and both have transformed how clinicians approach obesity management. But they are not the
GLP-1 side effects
Understanding GLP-1 Receptor Agonists and Their Side Effect Profile Glucagon-like peptide-1 (GLP-1) receptor agonists have become among the most prescribed medications in recent years, with FDA-approved formulations including semaglutide (Ozempic, Wegovy) and tirzepatide gaining particular prominence for weight management. As with all pharmacologically active compounds, GLP-1 agonists produce a characteristic
Tirzepatide
The Dual Mechanism: Understanding Tirzepatide's GIP/GLP-1 Action Tirzepatide represents a significant advancement in peptide pharmacology by targeting two distinct hormone receptors simultaneously. Unlike semaglutide, which functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism distinguishes